A study to evaluate the first dose of gentamicin needed to achieve a peak plasma concentration of 30 mg/l in patients hospitalized for severe sepsis.

scientific article published on 3 May 2016

A study to evaluate the first dose of gentamicin needed to achieve a peak plasma concentration of 30 mg/l in patients hospitalized for severe sepsis. is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1008759631
P356DOI10.1007/S10096-016-2652-6
P698PubMed publication ID27142585

P50authorDorothée ValanceQ87383375
Jerome AllynQ64900383
P2093author name stringL Corradi
O Martinet
N Allou
P Augustin
D Vandroux
T Galas
Y Charifou
P2860cites workSurviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012Q29615429
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesQ29615686
Therapeutic drug monitoring of amikacin in septic patients.Q33754166
Revisiting the loading dose of amikacin for patients with severe sepsis and septic shockQ33919190
Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoringQ34061646
Aminoglycoside dosing weight correction factors for patients of various body sizesQ35111974
Dynamic changes of microbial flora and therapeutic consequences in persistent peritonitisQ35162610
Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care unitsQ37247721
Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis.Q40474926
Assessment of the National French recommendations regarding the dosing regimen of 8mg/kg of gentamicin in patients hospitalised in intensive care units.Q40692247
Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrationsQ41348554
Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentrationQ44483617
EUCAST technical note on Amphotericin B.Q47575248
Electronic bed weighing vs daily fluid balance changes after cardiac surgeryQ48921033
Once- versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. Scandinavian Amikacin Once Daily Study Group.Q50529699
Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoringQ84537814
First-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patientsQ86127368
P433issue7
P921main subjectgentamicinQ422482
sepsisQ183134
P304page(s)1187-1193
P577publication date2016-05-03
P1433published inEuropean Journal of Clinical Microbiology & Infectious DiseasesQ15754378
P1476titleA study to evaluate the first dose of gentamicin needed to achieve a peak plasma concentration of 30 mg/l in patients hospitalized for severe sepsis
P478volume35

Reverse relations

Q38432516Short-Course Adjunctive Gentamicin as Empirical Therapy in Patients With Severe Sepsis and Septic Shock: A Prospective Observational Cohort Studycites workP2860

Search more.